Skip to content

Trial · Interventional

Not yet recruitingPhase 4Registry data

Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery

Overview

Status
Not yet recruiting
Phase
Phase 4
Enrollment
20 participants (estimated)
Sponsor
Chinese University of Hong Kong · Other
Design
Allocation not applicable · Open label (no masking)
Countries
Not stated
Start
1 Oct 2026 (estimated)
Primary completion
1 Oct 2027 (estimated)
Completion
1 Oct 2028 (estimated)
First posted
6 Oct 2026
Last update posted
6 Oct 2026
Conditions
Colorectal Cancer · Colorectal Surgery · Ureteric Injury

Timeline

1 trial · 1 not yet recruiting

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2026202720282029
  1. Ph 4

    Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery

    NCT07861815

    est. 1 Oct 2026 to est. 1 Oct 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study will assess whether methylene blue fluorescence imaging can help surgeons identify the ureters during colorectal surgery. Methylene blue, given through a vein during the operation, is taken up and excreted by the kidneys, allowing the ureters to appear under a special fluorescence camera system. The study will include adults undergoing open, laparoscopic, or robotic colorectal surgery at Prince of Wales Hospital. The surgeons will compare ureter visibility using standard white light with visibility using fluorescence imaging at different stages of the operation. The study will also assess the best dose of methylene blue, the additional time required, the ease of using the imaging system, and whether the imaging findings affect the surgical plan. The study's hypothesis is that methylene blue fluorescence imaging will make it easier or faster to identify the ureters than white light alone. The technique will be considered feasible if it is helpful in at least 20% of operations-for example, by identifying a ureter earlier or identifying it when it cannot be seen under white light. The findings will help determine whether a larger future study should be conducted.

Interventions

  • Intravenous Methylene BlueDrug
  • Methylene Blue Fluorescence Imaging SystemDevice

Arms1

  • Experimental

    Methylene Blue Fluorescence Imaging Arm

    Intravenous Methylene Blue with Fluorescence Imaging for Ureter Identification

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Proportion of cases in which fluorescence imaging with methylene blue is deemed helpful for identifying the index ureter

    Time frame · Intraoperative - at three predefined stages of the index operation (before dissection, before division of critical structures, and after specimen removal)

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Aged ≥18 years * Scheduled to undergo open, laparoscopic or robotic colorectal surgery, including right colectomy, extended right colectomy, left colectomy, high anterior resection, low anterior resection, abdominoperineal resection, subtotal colectomy and total colectomy. Exclusion Criteria: * Unable to understand the aims and objectives of this study and unable to give consent for participation * Known allergy to methylene blue * Pregnant * Taking selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, or tricyclic antidepressants (risk of serotonin syndrome) * Significant renal or hepatic impairment * Presence of renal or ureteric obstruction * History of G6PD deficiency (risk of hemolytic anemia)

PepBank is a research reference. Talk to a doctor before you use any peptide.